AI Use Needs Docs' Consent | ColoSense Shows 94.4% Sensitivity For CRC
Praveen Suthrum
Cofounder, NextServices | Author, The Shift, Scope Forward | GI Mastermind
The AMA calls for physician consent in some AI uses in medicine, advocating for limited physician liability and greater transparency in insurers' AI decision-making systems.
Blue Cross Blue Shield Massachusetts' new policy will stop covering monitored anesthesia care for some GI procedures without specific risk factors, possibly affecting patient care and efficiency.
The ColoSense multitarget stool RNA test demonstrates high sensitivity for detecting colorectal cancer and advanced adenomas, offering a promising noninvasive screening option.
JAK inhibitors, led by AbbVie’s Rinvoq, are increasingly used in ulcerative colitis treatment in the US, challenging traditional therapies.
Higher vitamin D levels before treatment improved colonoscopy results in ulcerative colitis and led to better nutrition and supplementation in Crohn disease patients.
At 3 and 6 months, enrolled patients showed a 72% and 64% reduction in GI-related emergency department visits compared to non-enrolled patients, with rates dropping from 17% to 5% and 21% to 8%, respectively.
A study found no colorectal cancers three years after a negative multi-target stool DNA test, suggesting a three-year interval for such screenings is clinically appropriate.
领英推荐
Pristine Surgical has expedited the release of its Summit 4K single-use surgical arthroscope to enhance the efficiency, consistency, and safety of endoscopy procedures.
In 2024, gastroenterologists are focusing on staff engagement, contract management, and exploring the impact of AI in gastroenterology, including its use in colon cancer screening and Barrett's esophagus surveillance.
Elizabeth Paine, MD, outlines how having clear and thorough parental leave policies promotes inclusivity and job retention in gastroenterology.
November 2023 in gastroenterology featured an FDA approval for erosive esophagitis treatment, discontinuation of a phase 3 ulcerative colitis program, and insights into Clostridioides difficile testing and risk factors.
Emerging initiatives gain momentum as organizations explore the future of virtual care, personalized genomics and patient-centric approaches.
For weekly gastroenterology business/tech updates directly in your inbox, subscribe to the?Scope Forward newsletter.